(Q43973278)

English

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial

scientific article published on 9 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial (English)

1 reference

Europe PubMed Central

28 November 2017

chemoradiotherapy

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

4

1 reference

Europe PubMed Central

28 November 2017

David Sebag-Montefiore

object named as

David Sebag-Montefiore

17

0 references

Robert Glynne-Jones

2

object named as

Robert Glynne-Jones

1 reference

Europe PubMed Central

28 November 2017

author name string

Roger D James

1

1 reference

Europe PubMed Central

28 November 2017

Helen M Meadows

3

1 reference

Europe PubMed Central

28 November 2017

Arthur Sun Myint

5

1 reference

Europe PubMed Central

28 November 2017

Mark P Saunders

6

1 reference

Europe PubMed Central

28 November 2017

Timothy Maughan

7

1 reference

Europe PubMed Central

28 November 2017

Alec McDonald

8

1 reference

Europe PubMed Central

28 November 2017

Sharadah Essapen

9

1 reference

Europe PubMed Central

28 November 2017

Martin Leslie

10

1 reference

Europe PubMed Central

28 November 2017

Stephen Falk

11

1 reference

Europe PubMed Central

28 November 2017

Charles Wilson

12

1 reference

Europe PubMed Central

28 November 2017

Simon Gollins

13

1 reference

Europe PubMed Central

28 November 2017

Rubina Begum

14

1 reference

Europe PubMed Central

28 November 2017

Jonathan Ledermann

15

1 reference

Europe PubMed Central

28 November 2017

Latha Kadalayil

16

1 reference

Europe PubMed Central

28 November 2017

publication date

9 April 2013

1 reference

Europe PubMed Central

28 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

28 November 2017

14

1 reference

Europe PubMed Central

28 November 2017

6

1 reference

Europe PubMed Central

28 November 2017

516-524

1 reference

Europe PubMed Central

28 November 2017

Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970086-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70086-X

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43973278&oldid=2105180521"